Next Article in Journal
Influenza Vaccination and Non-Pharmaceutical Measure Effectiveness for Preventing Influenza Outbreaks in Schools: A Surveillance-Based Evaluation in Beijing
Next Article in Special Issue
BCG Provides Short-Term Protection from Experimental Cerebral Malaria in Mice
Previous Article in Journal
Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control Assay
Previous Article in Special Issue
Immune System Modulations by Products of the Gut Microbiota
Review

Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin

1
Department of Experimental Medicine, University of Perugia, 06132 Perugia, Italy
2
Department of Internal Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 713; https://doi.org/10.3390/vaccines8040713
Received: 19 October 2020 / Revised: 19 November 2020 / Accepted: 27 November 2020 / Published: 1 December 2020
The immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a critical factor in the clinical presentation of COVID-19, which may range from asymptomatic to a fatal, multi-organ disease. A dysregulated immune response not only compromises the ability of the host to resolve the viral infection, but may also predispose the individual to secondary bacterial and fungal infections, a risk to which the current therapeutic immunomodulatory approaches significantly contribute. Among the secondary infections that may occur in COVID-19 patients, coronavirus-associated pulmonary aspergillosis (CAPA) is emerging as a potential cause of morbidity and mortality, although many aspects of the disease still remain unresolved. With this opinion, we present the current view of CAPA and discuss how the same mechanisms that underlie the dysregulated immune response in COVID-19 increase susceptibility to Aspergillus infection. Likewise, resorting to endogenous pathways of immunomodulation may not only restore immune homeostasis in COVID-19 patients, but also reduce the risk for aspergillosis. Therefore, CAPA represents the other side of the coin in COVID-19 and our advances in the understanding and treatment of the immune response in COVID-19 should represent the framework for the study of CAPA. View Full-Text
Keywords: COVID-19; Aspergillus; anakinra; Aryl Hydrocarbon Receptor; thymosin alpha 1 COVID-19; Aspergillus; anakinra; Aryl Hydrocarbon Receptor; thymosin alpha 1
MDPI and ACS Style

Costantini, C.; van de Veerdonk, F.L.; Romani, L. Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin. Vaccines 2020, 8, 713. https://doi.org/10.3390/vaccines8040713

AMA Style

Costantini C, van de Veerdonk FL, Romani L. Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin. Vaccines. 2020; 8(4):713. https://doi.org/10.3390/vaccines8040713

Chicago/Turabian Style

Costantini, Claudio, Frank L. van de Veerdonk, and Luigina Romani. 2020. "Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin" Vaccines 8, no. 4: 713. https://doi.org/10.3390/vaccines8040713

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop